English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/113975
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Molecular bases of schizophrenia | Bases moleculares de la esquizofrenia

AuthorsGiménez Martín, Cecilio
Issue Date2012
PublisherReal Academia Nacional de Farmacia (España)
CitationAnales de la Real Academia Nacional de Farmacia 78: 365- 385 (2012)
AbstractSchizophrenia is a complex disorder that affects about 1% of the world population and is one of the most important causes of chronic disability. Although its etiology is unknown, the disease involves various morphologic and neurochemical abnormalities and it it's accepted that genetic factors, either alone or enhanced by environmental and epigenetic factors play a role in its pathogenesis. Numerous studies over the last forty years have involved alterations in biogenic amines mediated neurotransmission, GABAergic and glutamatergic neurotransmission to the pathology of schizophrenic psychoses. Recently, the knowledge of susceptibility genes and proteins involved in the pathology of the disease, are allowing early diagnosis and the development of a new generation of compounds that can act as antipsychotics more selectively.
Identifiersissn: 1697-428X
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.